Determination of Doxycycline in Human Plasma by Liquid Chromatography-Mass Spectrometry after Liquid-Liquid Extraction and its Application in Human Pharmacokinetics Studies

Muralidharan Selvadurai, Subramania Nairn Meyyanathan*, Sekar Rajan, Govindarajan Padmanaban and Bhojraj Suresh
Department of Pharmaceutical Analysis, J.S.S.College of pharmacy, Ootacamund 643001, Tamilnadu, India

Abstract
A sensitive and reproducible liquid chromatography–mass spectrometric (LC-MS) method has been developed and validated for the quantification of doxycycline in human plasma, after liquid-liquid extraction (LLE). Best chromatographic resolution was achieved on a reverse-phase Phenomenex C18 column using the mobile phase acetonitrile–5mM ammonium acetate (80:20) in isocratic elution with a total run time of 3.5 min. The analyte, doxycycline was detected by using an electrospray ionization mass spectrometer in the selected ion monitoring (SIM) mode. Linear plot was obtained in the concentration range of 0.5–5.0 μg/ml (r² = 0.998). Lower limit of quantification (LLOQ) was found to be 100 ng/ml in 500μl of plasma. Average recovery of the analyte was found to range from 96.08 to 104.60% in plasma at the concentrations of 1.0, 3.0 and 5.0 μg/ml. Intra- and inter-day relative standard deviation was found to be 0.13-0.74 and 0.11-0.34 respectively. The present method was successfully applied in the pharmacokinetic study of doxycycline in human plasma.

Keywords: Doxycycline; LC-MS; Validation; Pharmacokinetic studies

Introduction
Doxycycline a member of tetracycline antibiotic group is commonly used to treat chronic prostatitis and syphilis. Doxycycline shows its poor ultraviolet (UV) absorption characteristics. Hence determination of doxycycline using HPLC-UV will be a hard task, lacks sensitivity and requires long chromatographic run time in biological fluids. Due to the high polarity index of doxycycline, the gas chromatographic (GC) method requires complex and time-consuming derivatization procedures. Limited analytical techniques were available in the assay of doxycycline such as HPLC-DAD as well as liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). Compared to reported methods (Axisa et al., 2000; Bocker et al., 1983; Cinquina et al., 2003; Croubels et al., 1998; Fiori et al., 2005; Sanderson et al., 2005; Oka et al., 1997; Ruz et al., 2004; Skulason et al., 2003; Santos et al., 1996; Sheridan et al., 1988; Gschwend et al., 2007; Alsarra et al., 2004; Balogh et al., 1991) the present liquid chromatography–mass spectrometry method is relatively simple, rapid and highly sensitive in the determination of doxycycline in human plasma after liquid-liquid extraction (LLE) and has been successfully applied in the human pharmacokinetic study.

Experimental
Chemicals and reagents
Reference standards of doxycycline (purity: 99.67%) and oxytetracycline (internal standard, IS 99.01%) were procured from M/s. Orchid pharmaceuticals (Chennai, India) and Cadila Pharm (Ahmedabad, India) respectively. HPLC grade acetonitrile was procured from E. Merck (Mumbai, India) and other chemicals used were of analytical grade. Purified water from a Milli-Q-system (Millipore, Bangalore, India) was used throughout the analysis.

Human
Human studies were approved by human ethical committee, Ooty, India.

Instrumentation
A Shimadzu 2010 A LC–MS (including two LC-10Advp pumps) an online vacuum deaerator, a constant temperature automatic sampler, a single quadrupole mass spectrometer equipped with an electrospray ionization interface (ESI) source and LC–MS solution was used for data processing.

Chromatographic conditions
Liquid chromatographic separations were achieved using a Phenomenex 5μ C18 column (100 mm×4.6 mm). The column and auto sampler tray temperature were kept constant at 40° and 4°C, respectively. The mobile phase consisted of a mixture of acetonitrile:5mM ammonium acetate (80:20) and was delivered at a flow-rate of 0.3 ml/min. The sample injection volume was 10 μl.

Mass spectrometric conditions
Samples were ionized by positive-ion electrospray ionization mode under the following source conditions: gas flow: 2.5 l/min; curved desolvation line (CDL) voltage was fixed as in tuning, CDL temperature: 250°C; and block temperature: 200°C. Mass spectra were obtained at a dwell time of 0.2 and 1s for SIM and scan mode accordingly. Analysis was carried out using selected ion monitoring (SIM) for specific m/z 444.0 for doxycycline and m/z 460.0 for oxy

*Corresponding author: Dr. Subramania Nairn Meyyanathan Ph.D., Professor and Head, Department of pharmaceutical Analysis, J.S.S.College of pharmacy, Ootacamund-643001, Tamilnadu, India, E-mail: meyyys@rediffmail.com

Received July 15, 2010; Accepted September 16, 2010; Published September 16, 2010


Copyright: © 2010 Selvadurai M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
tetracycline. Peak areas for all components were automatically integrated using LC/MS lab solution Version 2.04 (© 2010 A Shimadzu Corp.).

**Preparation of stock solution and sample solutions**

Stock solution of doxycycline was prepared by dissolving the accurately weighed reference compound in water and acetonitrile (1:1) to give a final concentration of 1 mg/ml, stored at 4°C until it is used. The solution was then serially diluted with water and mixed with blank human plasma to achieve standard working solutions at concentration of 0.5, 1.0, 2.0, 3.0, 4.0, and 5.0 μg/ml for doxycycline, respectively. A 2500.0 ng/ml internal standard working solution was prepared by diluting the 1 mg/ml stock solution of internal standard with millipore water.

**Sample preparation**

A 0.5 ml aliquot of human plasma sample was mixed with 100μl of internal standard working solution (25000 ng/ml of oxytetracycline) and 1.0 ml of 0.05 M phosphate buffer of pH 7.0 were added and mixed. The resulting solution was vortexed and extracted with n-hexane. The upper organic layer was separated, evaporated and the drug was reconstituted using 0.5 ml of the mobile phase and analysed.

**Assay Validation (FDA 2001)**

**Sensitivity and specificity:** The lower limit of quantification was determined as the minimum concentration that could be accurately and precisely quantified (lowest data point of the standard curve). The specificity of the assay for the analytes versus endogenous substances in the matrix was assessed comparing the lowest concentration in the calibration curves with reconstitutions prepared with drug-free plasma from five different humans. Limit of detection was found to be 50 ng/ml and Limit of quantification is 100 ng/ml.

**Accuracy and precision:** The accuracy and precision (presented as relative standard deviation, R.S.D.) of the assay were determined using quality control (QC) samples at 1.0, 3.0 and 5.0 μg/ml. Accuracy (%) was determined by the percentage ratio of measured over spiked QC concentration (mean of measured/ spiked×100%). Intra-day precision was determined by analyzing replicate aliquots of QCs (n = 5 per each concentration) on the same day. Inter-day precision was determined by repetitive analysis of QC samples (each concentration) on five consecutive days.

**Recovery and ionization:** To investigate the recovery of doxycycline by the LLE method, plasma samples were spiked with doxycycline at concentrations of 1.0, 3.0 and 5.0 μg/ml. The resulting peak–area ratios (analyte: internal standard) were compared with that of the standards prepared in mobile phase to provide the recovery values. Ion suppression of ionization was evaluated by APCI technique, the absolute peak areas of control plasma extracted and then spiked with a known amount of drug, to neat standards injected directly in the same reconstituted solvent.

**Stability:** To evaluate sample stability after three freeze–thaw cycles and at room temperature, five replicates of QC samples at each of the low, medium and high concentrations were subjected to three freeze–thaw cycles or were stored at room temperature for 4 h before sample processing, respectively. Five replicates of QC samples at each of the low and high concentrations were processed and stored under autosampler conditions for 24 h. Stability was assessed by comparing the mean concentration of the stored QC samples with the mean concentration of freshly prepared QC samples.

**Clinical design:** The study protocol was approved by the Institution ethics committee. Twenty four healthy male Indian subjects with mean age group 20–30 years and average weight 65.8 ± 6.1 kg were included in the study. Subjects were excluded from the study if one or more of following criteria were present at time of medical screening: allergic to doxycycline, history or clinical data of renal or liver disease, positive test for hepatitis B, HIV, history of alcohol, drug addiction or donated blood within 72 days prior to study. Test and reference formulations of doxycycline 100 mg tablet were administered with 240 ml of water. The study was conducted single dose, randomized, open, and complete crossover design. Volunteers were fasted overnight before and 4 h after drug administration. Blood sample (5 ml) were collected at 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.0, 6.0, 8.0, 12.0, 18.0 and 24.0 h of post drug administration through an indwelling cannula into heparinised glass vials. After drug administration standard breakfast and lunch were provided at 4 and 6 h post dose. The blood samples were immediately centrifuged, plasma was separated and stored at -20°C until analysed. After a washout period of 7 days, the study was repeated in the same manner to complete the crossover design. The plasma samples obtained at various time intervals were analysed by the HPLC method developed.

**Application of the assay:** The developed LC-MS assay method was used in the pharmacokinetic study after oral (100.0 mg) administration of doxycycline to human volunteers. Volunteers were fasted for 12 h before dosing and 4 h afterwards, with free access to water. The samples were collected in pre-labeled vacutainers containing sodium citrate as the anti coagulant and centrifuged at 4000 rpm for 10 min at 15°C and plasma was collected in pre-labeled sample collection tube. A wash out period of 7 days was observed between the two phases of the study. The samples were stored in the deep freezer at -70 ± 5°C until analyzed by a validated LC-MS method.

---

**Figure 1:** Mass Spectrum of doxycycline at Positive mode Scan.
Results and Discussion

Method development

Doxycycline is a water soluble drug. Hence, an attempt has been made to extract the drug from plasma by precipitating the plasma samples with solvents like acetonitrile, perchloric acid and methanol. It was found that the analyte recovery was less with these precipitating agents, may be due to decrease in the solubility of doxycycline in water after the addition of these solvents. Therefore liquid-liquid extraction procedure was tried using dichloromethane as extracting solvent. But due to the interference from blank plasma sample when extracted with dichloromethane, a non-polar solvent like n-hexane was tried. Being less polar than dichloromethane it was found that there were no interference from plasma samples when extracted with n-hexane. This proves the satisfactory with n-hexane. The extraction was carried out in one simple step in 0.05 M phosphate buffer (PH 7.0), which removed interferences due to plasma and yielded cleaner chromatograms. Thus n-hexane was used for sample preparation.

Validation

Specificity: The full scan mass spectra of doxycycline after direct injection in mobile phase are presented in Figure 1. The predominant protonated molecules found for doxycycline were m/z 444.00. The mass spectrometric parameters were optimized to obtain the higher signal for the selected ion 460.00, which also showed less internal interference. While using the isocratic programme, observed retention times were about 2.4 and 3.1 min for doxycycline and oxytetracycline, respectively. No additional peaks due to endogenous substances that could have interfered with the detection of the compounds of interest were observed. Representative chromatograms for blank plasma (Figure 2), doxycycline and oxytetracycline in volunteers sample are presented in (Figure 3).

Linearity and lower limit of quantification: The linear regression analysis of doxycycline constructed by plotting the peak–area ratio of doxycycline to the internal standard (y) versus analyte concentration (µg/ml) in spiked plasma samples (x). The average regression equation of these curves and their correlation coefficients (r) were calculated as follows: y = 0.050 - 0.001 (r² = 0.998, n = 7), weighting coefficient: 1/x; it showed good linear relationship between the peak areas and the concentrations. The lower limit of quantitation, defined as the lowest concentration analyzed with accuracy within ±15% and a precision ±15%, was 5 ng/ml for determination of doxycycline in plasma. The limit has already been sufficient for pharmacokinetic studies of doxycycline.

Precision: The intra-day precision (presented as relative standard deviation) is shown in Table 1. The precision for concentrations of doxycycline were 6.21, 8.71 and 9.15%, respectively. The accuracy, defined as (measured concentration/spiked concentration) ×100%, reached from 95.72 to 98.53% throughout the four concentrations.
Recovery and stability: The absolute recoveries of doxycycline at concentrations of 1.0, 3.0 and 5.0 μg/ml (n = 5) were 95.60±5.75, 96.57±8.59 and 98.19±9.15%, respectively. Stability of doxycycline during sample handling (freeze–thaw and short-term temperature) and the stability of processed samples were evaluated and doxycycline was stable for at least 4 h at room temperature in plasma samples, for 24 h in autosampler conditions and in plasma samples following three freeze–thaw cycles.

Ionization: It was shown that LLE improves the sample clean-up to remove internal substances from plasma and thereby decrease the amount of matrix injected onto the column, thus the ion suppression effect was minimized. The results indicated that there was no significant difference between the signals of analytes extracted from human plasma and the mobile phase, which proves that there were no matrix effects.

Pharmacokinetic study: The assay was conducted to obtain pharmacokinetic data for doxycycline in human plasma after oral administration (100.0 mg) application of the LC/MS method developed here to in vivo pharmacokinetic studies in humans. The area under the plasma concentration (AUCs curve) of doxycycline after oral administrations was 24.67 and 25.50 μg h/ml, respectively. The mean $C_{\text{max}}$ value was 3.50 and 3.58 μg/ml corresponding mean $t_{\text{max}}$ value was 1.41 and 1.45 h. The mean plasma elimination half-life was 8.20 and 8.15 h. for test and reference respectively (Figure 4), other pharmacokinetic parameters in this study are shown in Table 2. The present method could be applied to pharmacokinetic studies of lower dose administration of doxycycline.

Conclusion

LLE of doxycycline from plasma was found to be more precise than the solid phase extraction. The current method guarantees a high precision, accuracy, recovery and a relatively short analysis time and will be a useful tool in the pharmacokinetic study of doxycycline in humans.
References


